Scientists' worst fears about Trump's cuts to research funding haven't come to pass, thanks to several legal challenges and ...
Eli Lilly delivered a robust 4Q25 beat, with revenue up 43% YoY and strong EPS growth, driven by its GLP-1 franchise. Check out my latest analysis on LLY stock.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果